Skip to main content
Funded Studies

Inhibition of LINGO-1 as a Novel Target for Regeneration in Pre-clinical PD Models

LINGO-1 inhibits growth responses in the central nervous system and LINGO-1 expression is increased when nerve cells are exposed to injury. We have shown that LINGO-1 expression is increased in vulnerable substantia nigra neurons in Parkinson’s disease (PD) patients, and also in a pre-clinical model of PD caused by alpha-synuclein overexpression. We therefore propose LINGO-1 inhibition as a therapeutic target for PD. Blocking LINGO-1 activity in vitro enhances neurite outgrowth of dopamine neurons. Moreover, eliminating the LINGO-1 gene (knockout) or application of LINGO-1 inhibitors prevents dopamine neurons from dying in pre-clinical models of PD caused by oxidative stress. We will now test LINGO-1 inhibition in an additional pre-clinical model of PD caused by alpha-synuclein overexpression.

Project Description: 
We will test the capacity of LINGO-1 inhibition to protect dopamine neurons from degeneration in a pre-clinical model of alpha-synucleinopathy. The clear genetic and neuropathological evidence for the role of alpha-synuclein in PD pathogenesis is the rationale for choosing this model. Our AAV-alpha-synucleinopathy model (using gene delivery of mutant alpha-synuclein) exhibits a slow pattern of degeneration of dopamine neurons, and we have shown that the cell death is preceded by several predegenerative changes, which we have characterized.  We will inject AAV- alpha-synuclein into LINGO-1-deficient pre-clinical models, and we will determine at different time points (8 and 24 weeks after injection) whether inhibition of LINGO-1 prevents alpha-synuclein-induced pathological changes to dopamine neurotransmission and dopamine neuron number.

Relevance to Diagnosis/Treatment of Parkinson’s Disease:  
Given our previous pre-clinical studies showing extensive neuroprotection by LINGO-1 blockade in oxidative stress models of PD, it is anticipated that inhibition of LINGO-1 will protect dopamine neurons from alpha-synuclein-mediated neuronal damage and dysfunction. We expect that this study will validate LINGO-1 inhibition as an appropriate target for the next phase of pre-clinical studies and potential clinical application.

Anticipated Outcome: 
Upon successful completion of this project, we will learn whether LINGO-1 inhibition can prevent neurotransmission changes and degeneration of substantia nigra dopamine neurons in an experimental model of PD caused by alpha-synuclein overexpression.




  • Ole Isacson, MD, PhD

    Boston, MA United States

  • Penelope Hallett, PhD

    Belmont, MA United States

Discover More Grants

Within the Same Program

Within the Same Funding Year

We use cookies to ensure that you get the best experience. By continuing to use this website, you indicate that you have read our Terms of Service and Privacy Policy.